Withaferin A
NFκB and angiogenesis inhibitor / Displays potent antiangiogenesis activity inhibiting endothelial cell sprouting in vitro (IC50 = 12 nM) and in vivo.1 Potently inhibits NF-κB activation by preventing TNFα-induced activation of IKKβ.2 Covalently binds to the intermediate filament protein, vimentin3 inducing its disassembly and serine 56 phosphorylation4. Inhibits reactive gliosis and blocks TNFα-mediated neuronal apoptosis in in vivo models.5
Biochemicals & reagents
5119-48-2
NSC-101088
1) Mohan et al. (2004), Withaferin A is a potent inhibitor of angiogenesis; Angiogenesis, 7 115 2) Kaileh et al. (2007), Withaferin A strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with inhibition of its kinase activity; J. Biol. Chem., 282 4253 3) Bargagna-Mohan et al. (2007), The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin; Chem. Biol., 14 623 4) Thaiparambil et al. (2011), Withaferin A inhibits breast cancer invasion and metastasis ast sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation; Int. J. Cancer, 129 2744 5) Livne-Bar et al. (2016), Pharmacologic inhibition of reactive gliosis blocks TNF-α-mediated neuronal apoptosis Cell Death Dis., 7 e2386
-20°C
TARGET: Cytoskeleton -- PATHWAY: NFkappaB; Apoptosis inhibitor; Cytokine -- RESEARCH AREA: Cell death; Angiogenesis -- DISEASE AREA: Cancer; Diabetes